Tacrolimus or Cyclosporine: Which Is the Better Partner for Mycophenolate Mofetil in Heart Transplant Recipients?
Authors:
- Bruno M. MeiserBMBruno M. Meiser
- Jan GroetznerJGJan Groetzner
- Ingo KaczmarekIKIngo Kaczmarek
- Peter LandwehrPLPeter Landwehr
- Markus MüllerMMMarkus Müller
- Sebastian JungSJSebastian Jung
- Peter ÜberfuhrPÜPeter Überfuhr
- Peter FraunbergerPFPeter Fraunberger
- Hans-Ulrich StempfleHSHans-Ulrich Stempfle
- Michael WeisMWMichael Weis
- Bruno ReichartBRBruno Reichart
- 27 August 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Transplantation
- Vol. 78 (4) , 591-598
Abstract
The aim of this single-center study was to investigate whether trough level adjusted mycophenolate mofetil (MMF) is more efficacious in combination with tacrolimus (TAC) or cyclosporine (CsA) and to evaluate the impact of either drug on MMF dosage. Sixty patients (TAC, n = 30; CsA, n = 30) undergoing heart transplantation were randomized into a prospective, open-label, controlled trial. Immunosuppression consisted of TAC or CsA in combination with MMF and corticosteroids. Target blood trough levels of TAC, CsA, and mycophenolic acid (MPA) were in the range of 10 to 15 ng/mL, 100 to 300 ng/mL, and 1.5 to 4.0 microg/mL, respectively. Acute rejection episodes (ARE); survival data; and adverse events with a special emphasis on infections, diabetes, hypertension, hypercholesterolemia, and the development of graft vessel disease (GVD) were recorded. Baseline characteristics were well balanced. All patients were successfully withdrawn from corticosteroids within 6 months of transplant. Freedom from acute rejection was significantly higher (P = 0.0001) and the incidence of ARE per 100 patient days significantly lower in the TAC-MMF group than in the CsA-MMF group (0.03 vs. 0.15; P = 0.00007). Overall patient survival during follow-up was similar (93% vs. 90%). To achieve the targeted MPA blood levels, a significantly lower dose of MMF was required for TAC versus CsA patients. After a follow-up time of 2 years, the mean GVD score was 1.85 +/- 3.18 in the TAC-MMF group and 3.95 +/- 4.8 in the CsA-MMF group (P = 0.08). At the selected doses and target levels for TAC and CsA used in this study, trough level adjusted MMF was more efficacious in combination with TAC for prevention of ARE. Furthermore, CsA patients need significantly more MMF to achieve similar MPA levels.Keywords
This publication has 18 references indexed in Scilit:
- Simvastatin Initiated Early After Heart TransplantationCirculation, 2003
- Suggested guidelines for the use of tacrolimus in cardiac transplant recipientsThe Journal of Heart and Lung Transplantation, 2001
- Transforming growth factor β in relation to cardiac allograft vasculopathy after heart transplantationThe Journal of Thoracic and Cardiovascular Surgery, 2000
- A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus11This study was sponsored by a grant from Fujisawa USA, Deerfield, Illinois.22The authors were working on behalf of the Tacrolimus US Heart Transplant Multicenter Study Group. Other members of the Study Group included (principal investigator listed first): UTAH Cardiac Transplant Program, Salt Lake City, Utah: David O. Taylor, MD, Dale G. Renlund, MD, Abdallah G. Kfoury, MD; St. Luke’s Episcopal Hospital/Texas Heart Institute, Houston, Texas: O. H. Frazier, MD, Branislav Radovancevic, MD, Edward K. Massin, MD; University of Wisconsin Hospitals and Clinics, Madison, Wisconsin: Robert M. Mentzer, Jr., MD, Charles C. Canver, MD, Robert B. Love, MD; Ochsner Medical Foundation, New Orleans, Louisiana: Frank W. Smart, MD, Hector O. Ventura, MD, Dwight D. Stapleton, MD, Mandeep Mehra, MD; University of Southern California, Los Angeles, California: Mark L. Barr, MD, Vaugh A. Starnes, MD; Medical College of Virginia, Richmond, Virginia: David E. Tolman, MD, Albert Guerraty, MD, David Salter, MD; Cleveland Clinic Foundation, Cleveland, Ohio: James B. Young, MD; Data Management and Statistical Coordinating Center-The EMMES Corporation, Potomac, Maryland: Paul VanVeldhuisen, MS, Anne Lindblad, PhD, Anita Yaffe, MSN, MPH.The Journal of Heart and Lung Transplantation, 1999
- Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoringThe Journal of Heart and Lung Transplantation, 1999
- The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levelsTransplantation Proceedings, 1999
- A RANDOMIZED ACTIVE-CONTROLLED TRIAL OF MYCOPHENOLATE MOFETIL IN HEART TRANSPLANT RECIPIENTS1Transplantation, 1998
- Mycophenolate MofetilDrugs, 1996
- Mode of Action of Tacrolimus (FK506): Molecular and Cellular MechanismsTherapeutic Drug Monitoring, 1995
- TacrolimusDrugs, 1993